Xenomics, Inc. (OTC
Bulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNA
diagnostic technologies, today announced patient enrollment has begun at
Italy's National Institute for Infectious Diseases "Lazzaro Spallanzani"
for a tuberculosis monitoring study using Xenomics' proprietary Transrenal
DNA (Tr-DNA) diagnostic technology.
"Xenomics has been developing a clinical diagnostic test for active
pulmonary tuberculosis based on detection of Mycobacterium specific DNA
sequences in patient's urine. We expect that the monitoring study will
extend applicability of our test to include monitoring of tuberculosis
treatment which is extremely important due to the significant rise in
reported drug-resistant forms of Mycobacterium. Our preliminary data looks
very promising and these studies will provide critical new data," said Dr.
L. David Tomei, CEO and Co-Founder of Xenomics.
Diagnosing and monitoring tuberculosis has always been difficult since
the definitive test for tuberculosis in use today is a culture which takes
up to several months to complete and is often unreliable. Therefore,
individuals with tuberculosis are often unaware of their condition during
that period and may be highly infectious. This is a serious problem in many
parts of the developing world and a growing problem in the USA.
"Xenomics' technology could provide accurate and immediate information
to physicians for diagnosis and monitoring purposes. Our propriety
technology is based upon the fact that fragmented cellular DNA from
throughout the body crosses the kidney barrier and accumulates in the
urine, a phenomenon originally discovered by our scientists" explained Dr.
Tomei. "Through the analysis of easily obtained small urine specimens,
these Tr-DNA fragments provide current and vital information about a wide
range of conditions inside the body, including serious infectious
diseases."
About the National Institute for Infectious Diseases:
Established in 1936, the National Institute for Infectious Diseases
(Istituto Nazionale per la Malattie Infettive "Lazarus Spallanzani") is
devoted to the prevention, diagnosis and care of infectious diseases.
Centrally located in Rome, it is among the leading health care and research
institutions in Europe and throughout the world.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the
development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics'
patented technology uses safe and simple urine collection and can be
applied to a broad range of applications, including prenatal testing, tumor
detection and monitoring, tissue transplantation, infectious disease
detection, genetic testing for forensic identity determination, drug
development, and research to counter bioterrorism. Scientists from Xenomics
were the first to report that fragments of DNA from normal cell death cross
the kidney barrier and can be detected in urine. The Company believes that
its technology will open significant new markets in the molecular
diagnostics field. Xenomics has three issued U.S. patents covering
different applications of the technology for molecular diagnostics and
genetic testing and a corresponding allowed European patent for the
Company's prenatal testing applications. The Company has organized a joint
venture to conduct research on infectious disease detection with the
National Institute for Infectious Diseases (Istituto Nazionale per la
Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a
research and development company called SpaXen Italia, S.R.L. For
additional information, please visit xenomics. Xenomics' stock
trades under the symbol XNOM.OB and is also listed on the Frankfurt Stock
Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such
statements are indicated by words such as "expect," "might," "should,"
"anticipate" and similar words indicating uncertainty in facts and figures.
Although Xenomics believes that the expectations reflected in such forward-
looking statements are reasonable, it can give no assurance that such
expectations reflected in such forward-looking statements will prove to be
correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities
and Exchange Commission on May 16, 2006, actual results could differ
materially from those projected in the forward-looking statements as a
result of the following factors, among others: uncertainties associated
with product development, the risk that Xenomics will not obtain approval
to market its products, the risk that Xenomics' technology will not gain
market acceptance, the risks associated with dependence upon key personnel,
and the need for additional financing.
Xenomics, Inc.
xenomics